The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global superdisintegrants market reached a value of US$ 361.7 Million in 2021. Looking forward, IMARC Group expects the market to reach US$ 551.3 Million by 2027, exhibiting at a CAGR of 7.45% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Superdisintegrants are modified disintegrants added in drug formulations to facilitate the breakup or disintegration of tablets or capsules into smaller particles. They assist in increasing the absorption of the drug and the solubility of active pharmaceutical ingredients (APIs) in the body, thereby reducing the disintegration time or oral solid dosage forms and enhancing their efficiency. They are utilized at a low level in the solid dosage form, generally 1- 10% by weight relative to the total weight of the dosage unit. Presently, they are available in synthetic and natural variants and used in many therapeutic areas, such as cardiovascular, infectious, hematological, neurological, gastrointestinal diseases, and inflammatory diseases.
Solid dosage medicines currently hold a significant share in the pharmaceutical industry. This, coupled with the rising number of people suffering from various age-related and chronic diseases, represents one of the key factors strengthening the growth of the market. Moreover, the extensive usage of superdisintegrants in the production of orally disintegrating tablets (ODTs) for antipsychotics, antidepressants, antimigraine, and sedatives is offering lucrative growth opportunities to industry investors. Apart from this, features like high compatibility, improved bioavailability, and efficient compressibility are catalyzing the demand for superdisintegrants worldwide. Additionally, leading players are considerably investing in product development and innovation of novel formulations to retain a competitive edge in the market. Besides this, stringent regulations are propelling the use of safer alternatives in the pharmaceutical industry, which is assisting in the wider acceptance of natural superdisintegrants around the world. Furthermore, the growing burden of neurological disorders, in confluence with the increasing popularity of telemedicine on account of the coronavirus disease (COVID-19) outbreak, is anticipated to impel the market growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global superdisintegrants market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on product, type, dosage form and therapeutic areas.
Breakup by Product:
Breakup by Type:
Breakup by Dosage Form:
Breakup by Therapeutic Areas:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Asahi Kasei Corporation, Ashland Global Specialty Chemicals Inc., Avantor Inc., BASF SE, Corel Pharma Chem, DFE Pharma GmbH & Co. KG, DuPont de Nemours Inc., JRS Pharma GmbH & Co. KG, Merck KGaA, Nippon Soda Co. Ltd., Roquette Frères and Sigachi Industries Limited.
|Base Year of the Analysis||2021|
|Segment Coverage||Product, Type, Dosage Form, Therapeutic Areas, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Asahi Kasei Corporation, Ashland Global Specialty Chemicals Inc., Avantor Inc., BASF SE, Corel Pharma Chem, DFE Pharma GmbH & Co. KG, DuPont de Nemours Inc., JRS Pharma GmbH & Co. KG, Merck KGaA, Nippon Soda Co. Ltd., Roquette Frères and Sigachi Industries Limited|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at